Clinical application of belimumab in lupus nephritis
As a human monoclonal antibody specific for B lymphocyte stimulator (BLyS), belimumab has recently become the first drug approved by the US Food and Drug Administration (FDA) for managing adult active lupus nephritis (LN). LN affects up to 60% of patients with systemic lupus erythematosus (SLE) and...
Saved in:
| Main Authors: | Zhou Han, Liang Wei, Ding Guo-hua |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2022-10-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails#10.3969/j.issn.1671-2390.2022.10.011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01) -
Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
by: Han Zhang, et al.
Published: (2023-12-01) -
Severe lupus nephritis with nephrotic syndrome after a treatment of belimumab: one case report
by: Gao Yue-ming, et al.
Published: (2021-01-01) -
Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
by: E. L. Nasonov, et al.
Published: (2021-09-01) -
Effect of biological agents on B-lymphocyte subpopulations in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2019-03-01)